Atezolizumab is a humanized IgG1 monoclonal anti-programmed death-ligand 1 (PD-L1) antibody that has been approved by the U.S Food Drug Administration (FDA) for various neoplastic conditions either as a single agent or in combination with other chemotherapeutic agents. Atezolizumab is a drug that is used in the management and treatment of various neoplastic conditions. It is in the monoclonal antibody class of medications. This activity covers the indications, contraindications, adverse events, and other therapeutic factors clinicians need to know to drive patient outcomes effectively.
- Provider:StatPearls, LLC
- Activity Link: https://www.statpearls.com/ArticleLibrary/viewarticle/130748
- Start Date: 2023-09-01 05:00:00
- End Date: 2023-09-01 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - MOC Credit Details: ABS - 1.0 Point; Credit Type(s): Accredited CME (ABS)
ABPATH - 1.0 Point; Credit Type(s): Lifelong Learning (ABPATH)
ABTS - 1.0 Point; Credit Type(s): Accredited CME (ABTS)
ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
ABS - 1.0 Point; Credit Type(s): Self-Assessment (ABS)
ABP - 1.0 Point; Credit Type(s): Lifelong Learning and Self-Assessment (ABP)
ABTS - 1.0 Point; Credit Type(s): Self-Assessment (ABTS) - Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Variable
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Adolescent Medicine, Cardiovascular, Chemical Pathology, Complex General Surgical Oncology, Endocrinology, Diabetes, and Metabolism, Female Reproductive, Gastroenterology, General Pediatrics, General Thoracic, Geriatric Medicine, GI (incl. Liver, Pancreas, Bilary), Hospital Medicine, Internal Medicine, Male Genital, Medical Oncology, Nephrology, Pulmonary Disease, Pulmonary, Mediastinum
Subscribe
Login
0 Comments
Oldest